Is Molina Healthcare (MOH) overvalued or fairly valued?

MarketChacha shows Molina Healthcare's valuation in context — a trailing P/E of about 26.3, a forward P/E of about 20.8, a price-to-book of about 2.5 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

What is Molina Healthcare's revenue?

Molina Healthcare reported revenue of $45.4B for FY2025, with net profit of $472.0M, per official filings.

What is the share price of Molina Healthcare (MOH)?

Molina Healthcare last traded at $203.06 (-1.3% on the day), as of 8/17/2026 — a delayed quote shown for education, not investment advice.

Molina Healthcare

MOH · NYSE · Healthcare · United States

Snapshot

TickerMOH

ExchangeNYSE

SectorHealthcare

IndustryHealthcare Plans

CountryUnited States

Employees19,000

HeadquartersLong Beach, United States

Websitewww.molinahealthcare.com

Filings tracked18

About Molina Healthcare

Molina Healthcare, Inc. provides managed healthcare services to low-income families and individuals under the Medicaid and Medicare programs and through the state insurance marketplaces in the United States. It operates in four segments: Medicaid, Medicare, Marketplace, and Other. The company was founded in 1980 and is headquartered in Long Beach, California.

Who owns it

Insiders1.4%
Institutions98.6%
Public & other0.0%

799 institutional holders

Ownership breakdown from public market data.

Top holders

Blackrock Inc.12.59%
AQR Capital Management, LLC6.82%
Vanguard Portfolio Management LLC5.35%
Capital World Investors4.91%
Lingotto Investment Management LLP4.81%
Vanguard Capital Management LLC4.51%
Victory Capital Management Inc.3.79%
FMR, LLC3.58%

Largest institutional holders — last updated 6/30/2026.

Forensic scorecard

Over 3 years only 0.65× of reported profit became operating cash — the classic sign that headline earnings may be running ahead of the cash actually generated. Often explained by working capital funding growth; worth a closer look.

Cash conversion0.65×

Net margin trend3.2% → 1.0%

Margin has compressed by about 2.2 points over the period — profitability is trending down.

Growth qualityrev 15% · PAT -34%

Profit growth is broadly tracking revenue growth — the earnings trend looks operational rather than one-off.

Computed by MarketChacha from reported figures (SEC XBRL). Education, not a rating or recommendation.

What's expected next

Next quarter

Rev $11.9B · EPS 0.29

Est. earnings growth +122.1%

Next fiscal year

Rev $48.1B · EPS 8.55

Est. earnings growth +85.8%

Analyst consensus estimates — not the company's own guidance.

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: SEC XBRL

Annual

Quarterly · last 8

Revenue (FY2025)

$45.4B

Net margin

1.0%

ROE

11.6%

Revenue CAGR (2y)

+15.5%

Profit CAGR (2y)

-34.2%

EPS (FY2025)

8.92

Net profit (FY2025)

$472.0M

Ask MarketChacha about MOH

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

Financials

Yearly

Period	Revenue	Net profit	EPS	Net margin	ROE
FY2025	$45.4B	$472.0M	8.92	1.0%	11.6%
FY2024	$40.6B	$1.2B	20.42	2.9%	26.2%
FY2023	$34.1B	$1.1B	18.77	3.2%	25.9%

Quarterly

Period	Revenue	Net profit	EPS	Net margin
2026Q2	$10.9B	$60.0M	1.19	0.6%
2026Q1	$10.8B	$14.0M	0.27	0.1%
2025Q3	$11.5B	$79.0M	1.51	0.7%
2025Q2	$11.4B	$255.0M	4.75	2.2%
2025Q1	$11.1B	$298.0M	5.45	2.7%
2024Q3	$10.3B	$326.0M	5.65	3.2%
2024Q2	$9.9B	$301.0M	5.17	3.0%
2024Q1	$9.9B	$301.0M	5.17	3.0%
2023Q3	$8.5B	$245.0M	4.21	2.9%
2023Q2	$8.3B	$309.0M	5.35	3.7%
2023Q1	$8.1B	$321.0M	5.52	3.9%

Figures as reported, in reporting currency. Source: SEC XBRL.

Filings & announcements

2026

10-Q filing
SEC7/23/2026
8-K — Results of operations, Exhibits
SEC7/22/2026material
8-K — Reg FD disclosure, Exhibits
SEC6/10/2026material
8-K — Executive/director change, Bylaw/charter change, Shareholder vote results, Exhibits
SEC5/11/2026material
8-K — Reg FD disclosure, Exhibits
SEC5/8/2026material
10-Q filing
SEC4/23/2026
8-K — Results of operations, Exhibits
SEC4/22/2026material
8-K — Reg FD disclosure
SEC2/26/2026material
10-K filing
SEC2/10/2026
8-K — Material agreement, Material financial obligation, Material impairment, Exhibits
SEC2/6/2026material
8-K — Results of operations, Exhibits
SEC2/5/2026material

2025

8-K — Material agreement, Material financial obligation, Other events, Exhibits
SEC11/20/2025material
8-K — Reg FD disclosure, Exhibits
SEC11/18/2025material
8-K — Reg FD disclosure, Exhibits
SEC11/17/2025material
8-K — Reg FD disclosure, Exhibits
SEC11/14/2025material
10-Q filing
SEC10/23/2025
8-K — Results of operations, Exhibits
SEC10/22/2025material
8-K — Material agreement, Material financial obligation, Exhibits
SEC8/12/2025material

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed market data) are delayed and shown for reference only. Verify with the linked sources before acting.